- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05051722
Tirer parti des marqueurs d'ADN méthylé (MDM) dans la détection du cancer de l'endomètre, du cancer de l'ovaire et du cancer du col de l'utérus (ECHO)
Tirer parti des marqueurs d'ADN méthylé (MDM) dans la détection du cancer de l'endomètre, du cancer de l'ovaire et du cancer du col de l'utérus : une étude clinique de phase II
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma.
This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Detection of endometrial, ovarian, and cervical cancers at an early stage vastly increases the chances of cure and may also avert morbidity secondary to surgical staging, radiation, and/or chemotherapy. Despite the great successes of cervical cancer screening, comparable early detection methods for other gynecologic cancers and their precursors are not available. While nearly 1.5 million women per year in the United States are evaluated for abnormal uterine bleeding (AUB) or postmenopausal bleeding (PMB), the most common symptom of endometrial cancer, most undergo an invasive diagnostic biopsy with the finding of benign etiology.
Vaginal bleeding is often the only presenting symptom of women ultimately diagnosed with endometrial cancer (EC) or its precursor lesion, endometrial hyperplasia(EH). More than 90% of women with EC present with vaginal bleeding. Cervical cancer and cervical dysplasia can present as intermenstrual bleeding, post-coital bleeding, or other abnormal vaginal bleeding. However, most women who present with AUB or PMB have a benign etiology.
There are approximately 70 million women ≥45 years of age in the United States based on the most recent census data. Between 4-11% of women will be worked up for perimenopausal AUB or PMB in their lifetime. As only 5-10% of those women will have an EC or EH, there is a great clinical need for a less invasive clinical diagnostic test that can reliably distinguish between benign uterine bleeding and bleeding associated with an underlying endometrial cancer, cervical cancer, or a precursor lesion.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Maureen A Lemens, BSN
- Numéro de téléphone: 507-293-1487
- E-mail: lemens.maureen@mayo.edu
Sauvegarde des contacts de l'étude
- Nom: Clinical Trials Referral Office
- Numéro de téléphone: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Recrutement
- Mayo Clinic
-
Chercheur principal:
- Kristina A. Butler, M.D.
-
Contact:
- Favy Trujillo
- Numéro de téléphone: 480-574-1468
- E-mail: trujillo.faviola@mayo.edy
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32224
- Recrutement
- Mayo Clinic
-
Contact:
- Ashley N Shelton, CRC
- Numéro de téléphone: 504-953-1594
- E-mail: Shelton.Ashley@mayo.edu
-
Chercheur principal:
- Tri A. Dinh, M.D.
-
Miami, Florida, États-Unis, 33173
- Recrutement
- Genoma Research, Inc.
-
Contact:
- Laura Lucia, BHSc, CRC
- Numéro de téléphone: 305-392-1264
- E-mail: lauralucia@genoma.comcastbiz.net
-
Chercheur principal:
- Guillermo Lievano, D.O.
-
Sous-enquêteur:
- Itsel Cardenas, PhD, APRN
-
Miami, Florida, États-Unis, 33156
- Actif, ne recrute pas
- My GYN Care
-
Orlando, Florida, États-Unis, 32806
- Recrutement
- Orlando Health
-
Contact:
- Donya Shahnavaz, CRC
- Numéro de téléphone: 321-841-7303
- E-mail: donya.shahnavaz@orlandohealth.com
-
Contact:
- Bianca Henry, CRC
- E-mail: bianca.henry@orlandohealth.com
-
Chercheur principal:
- Shelly M. Seward, M.D.
-
Pembroke Pines, Florida, États-Unis, 33029
- Actif, ne recrute pas
- Signature Women's Healthcare, LLC
-
Sarasota, Florida, États-Unis, 34239
- Recrutement
- Sarasota Memorial Health Care System
-
Chercheur principal:
- Toni P Kilts, D.O.
-
Contact:
- Anna Turnbull
- E-mail: Anna-Turnbull@smh.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30318
- Recrutement
- Piedmont Healthcare
-
Contact:
- Dionne Jean, CRC
- Numéro de téléphone: 404-425-7927
- E-mail: dionne.jean@piedmont.org
-
Chercheur principal:
- Leda Portia A. Gattoc, M.D.
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago
-
Contact:
- Veronika Sesari
- E-mail: vseseri@bsd.uchicago.edu
-
Chercheur principal:
- Kathryn Mills, M.D.
-
Contact:
- Calla O'Connor, MPH
- E-mail: calla.oconnor@bsd.uchicago.edu
-
Evergreen Park, Illinois, États-Unis, 60805
- Actif, ne recrute pas
- Providea Health Partners, LLC
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- Recrutement
- Ochsner Clinic Foundation
-
Chercheur principal:
- Diogo Torres, M.D.
-
Contact:
- Ashley Samuel, CRC
- Numéro de téléphone: 504-703-2658
- E-mail: ashley.samuel@ochsner.org
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Recrutement
- Henry Ford Health
-
Contact:
- Omayma Al Jabiry, CRC
- E-mail: oaljab1@hfhs.org
-
Contact:
- Ishita Narula, CRC
- E-mail: inarula1@hfhs.org
-
Chercheur principal:
- Ilinca Lupea, M.D.
-
Saginaw, Michigan, États-Unis, 48602
- Recrutement
- Valley OB-GYN Clinic
-
Contact:
- Jacqueline Lang, CCRC
- Numéro de téléphone: 989-272-9065
- E-mail: jacqueline.lang@elligodirect.com
-
Chercheur principal:
- Olivia A. Phifer-Combs, M.D.
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic
-
Contact:
- Maureen A Lemens, BSN
- Numéro de téléphone: 507-293-1487
- E-mail: lemens.maureen@mayo.edu
-
Chercheur principal:
- Jamie N. Bakkum-Gamez, MD
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39213
- Recrutement
- University of Mississippi Medical Center
-
Chercheur principal:
- Rodney Rocconi, M.D.
-
Contact:
- Kenna H Nettles, PA-C
- Numéro de téléphone: 601-815-5963
- E-mail: knettles1@umc.edu
-
Contact:
- Adriana Dodson, RN
- Numéro de téléphone: 601-984-1962
- E-mail: adodson2@umc.edu
-
-
New York
-
Howard Beach, New York, États-Unis, 11414
- Recrutement
- The Woman's Health Pavilion
-
Contact:
- Monica Martinez, CRC
- Numéro de téléphone: 718-843-6300
- E-mail: mmartinez@ilovemygyn.com
-
Chercheur principal:
- Andre H. Saad, M.D.
-
Westbury, New York, États-Unis, 11590
- Recrutement
- The Woman's Health Pavilion
-
Contact:
- Monica Martinez, CRC
- Numéro de téléphone: 718-843-6300
- E-mail: mmartinez@ilovemygyn.com
-
Chercheur principal:
- Andre H. Saad, M.D.
-
-
North Dakota
-
Grand Forks, North Dakota, États-Unis, 58206
- Recrutement
- Altru Health System
-
Chercheur principal:
- Collette Lessard, M.D.
-
Contact:
- Morgan Podell, CRC
- Numéro de téléphone: 701-780-6161
- E-mail: mlpodell@altru.org
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Recrutement
- Cleveland Clinic Foundation
-
Contact:
- Tori Carpenter, CRC
- E-mail: carpent3@ccf.org
-
Contact:
- Sarah Neale, CRC
- E-mail: neales@ccf.org
-
Chercheur principal:
- Michelle L. Kuznicki, M.D.
-
-
Texas
-
Houston, Texas, États-Unis, 77018
- Recrutement
- Total Women's Care of the Heights
-
Chercheur principal:
- Vonne Jones, M.D.
-
Contact:
- Tatiana Rivera
- Numéro de téléphone: 346-330-5302
- E-mail: tatiana.rivera@twcheights.com
-
Katy, Texas, États-Unis, 77450
- Recrutement
- Medical Colleagues of Texas, LLP
-
Contact:
- Erika Keller, CRC
- Numéro de téléphone: 281-769-8674
- E-mail: erika.keller@elligodirect.com
-
Chercheur principal:
- Kelly A. McCullagh, M.D.
-
-
Virginia
-
Richmond, Virginia, États-Unis, 23219
- Recrutement
- Virginia Commonwealth University/ Massey Cancer Center
-
Chercheur principal:
- Chelsea Salyer, M.D.
-
Contact:
- Priyanka Doneparthi, CRC
- E-mail: doneparthip@vcu.edu
-
Contact:
- Morgan DeHart, CRC
- Numéro de téléphone: 804-827-1266
- E-mail: dehart2@vcu.edu
-
-
Wisconsin
-
Eau Claire, Wisconsin, États-Unis, 54703
- Recrutement
- Mayo Clinic Health System - Northwest Wisconsin
-
Contact:
- Stephanie L Larson, ACRC
- Numéro de téléphone: 715-838-1976
- E-mail: larson.stephanie3@mayo.edu
-
Contact:
- Christina M Scinto, ACRC
- Numéro de téléphone: 715-464-8172
- E-mail: cinto.christina@mayo.edu
-
Chercheur principal:
- Blenda Yun, M.D.
-
La Crosse, Wisconsin, États-Unis, 54601
- Recrutement
- Mayo Clinic Health System - Southwest Wisconsin
-
Contact:
- Kate L Zboralski, ACRC
- Numéro de téléphone: 608-392-9521
- E-mail: zboralski.kathryn@mayo.edu
-
Contact:
- Taylor Cammer, ACRC
- Numéro de téléphone: 608-392-9280
- E-mail: cammer.taylor@mayo.edu
-
Chercheur principal:
- Rebecca A. Scarseth, D.O.
-
Milwaukee, Wisconsin, États-Unis, 53226
- Actif, ne recrute pas
- Medical College of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients presenting to a GYN or GYN Surgery Clinic for evaluation of symptoms or for consultation and planned procedures as outlined in the seven study cohort descriptions.
La description
Inclusion Criteria for Cohort 1:
Patients will be ≥45 years of age and meet one of the following criteria:
- Abnormal uterine bleeding
- Postmenopausal bleeding
OR
Patients ages 18 - 44 years of age and meet these criteria
- Abnormal uterine bleeding
- One risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use)
Exclusion Criteria for Cohort 1:
- Prior hysterectomy
- Current known pregnancy diagnosis
- Any prior pelvic or vaginal radiotherapy
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia
- Current biopsy-proven endometrial cancer or endometrial hyperplasia
- Current biopsy-proven benign endometrial polyp
- Endometrial biopsy/sampling within the preceding 1 month showing benign endometrium
Inclusion Criteria for Cohort 2:
Patients will be ≥18 years of age and meet at least one of the following criteria:
- Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection
- Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection, etc)
Exclusion Criteria for Cohort 2:
- Undergoing surgical procedure for recurrent or metastatic EC
- Received preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis
- Prior hysterectomy
- Current known pregnancy diagnosis
- Prior or current biopsy-proven cervical cancer
- Presence of concomitant biopsy-proven cervical dysplasia
- Any prior pelvic or vaginal radiotherapy
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Prior intervention or surgery with intent to completely remove the target pathology
Inclusion Criteria for Cohort 3:
Patients will be ≥18 years of age, have a cervix and meet at least one of the following criteria:
- History of current abnormal cervical/endocervical Pap test for which the patient is presenting for colposcopy
- Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated
- Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible)
Exclusion Criteria for Cohort 3:
- History of pelvic or vaginal radiotherapy
- Prior total hysterectomy (cervix removed) for any indication
- Current known pregnancy diagnosis
- Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass
- Prior intervention or surgery with intent to completely remove the target pathology for the current lesion / diagnosis during the current episode
Inclusion Criteria for Cohort 4:
Patients will be ≥45 years of age and should meet at least one of the following criteria:
- Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and/or clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps.
- Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed.
Exclusion Criteria for Cohort 4:
- Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis
- Any surgery within the past 3 months
- Prior hysterectomy
- Current known pregnancy diagnosis
- Prior or current biopsy-proven gynecologic cancer
- Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia
- Prior pelvic or vaginal radiotherapy
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis
- Prior intervention or surgery with intent to completely remove the target pathology for the current lesion / diagnosis during the current episode
Inclusion Criteria for Cohort 5:
Patients with a uterus will be ≥45 years of age and should meet the following criteria:
- Presenting for GYN wellness exam, ± Pap test
- No change in medical conditions, new diagnoses, or new medications within the past 6 months
Exclusion Criteria for Cohort 5:
- Pap test or cervical biopsy within the past 1 month
- Endometrial biopsy or office hysteroscopy within the past 1 month
- Any surgery within the past 3 months
- Prior hysterectomy
- Current known pregnancy diagnosis
- Prior or current biopsy-proven gynecologic cancer
- Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia
- Prior pelvic or vaginal radiotherapy
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Criteria met for inclusion in any of the other study cohorts
Inclusion Criteria for Cohort 6:
Patients ≥50 years of age and:
- Postmenopausal
- At least 1 intact ovary
- Diagnosis of an adnexal mass or a clinical suspicion of early-stage ovarian cancer (including fallopian tube cancer)
- Planned surgery for the adnexal mass
- For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion)
Exclusion criteria for Cohort 6:
- Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn)
- Chemotherapy for cancer treatment within the past 5 years prior to collection
- Clinically suspected advanced stage ovarian cancer (Stage III or IV) on presentation, if known prior to specimen collection
- Surgical candidates for recurrent ovarian cancer
- History of pelvic or vaginal radiation therapy
- Known current synchronous endometrial cancer or hyperplasia
- Known current cervical, vaginal, or vulvar dysplasia
Inclusion criteria for Cohort 7:
Women will be ≥18 years of age and meet the following criteria:
- Presence of clinically probable ovarian, fallopian tube, or primary peritoneal cancer (all under the umbrella of OC) based on clinical findings of any/all of the following: imaging showing adnexal and/or abdominal masses consistent with probable ovarian cancer, omental caking, elevated CA125, ascites, imaging-guided biopsy consistent with OC pathology
- Newly diagnosed with ovarian, fallopian tube or primary peritoneal cancer without neoadjuvant therapy
- At least one intact ovary
- For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion)
Exclusion criteria for Cohort 7:
- Patients with recurrent OC
- Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) within the past 5 years
- Chemotherapy for cancer treatment within the past 5 years prior to collection
- History of pelvic or vaginal radiation therapy
- Known current synchronous endometrial cancer or hyperplasia
- Known current cervical, vaginal, or vulvar dysplasia
- Current known pregnancy diagnosis
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Cohort 1 - AUB / PMB
Patients ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). Patients ages 18 - 44 years of age, presenting with abnormal uterine bleeding (AUB) and a risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Autres noms:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 2 - Biopsy-proven EC or AEH or EIN
Patients ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Autres noms:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 3 - Cervix pathology
Patients ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Autres noms:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 4 - Benign Uterine Pathology
Patients with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All patients enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Autres noms:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 5 - Healthy Control Women
Healthy patients with a uterus, ≥45 years of age presenting for GYN wellness exam to serve as a control group. These patients will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These patients will not have known or clinically suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Autres noms:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 6- Isolated Adnexal Mass Cohort (ovarian or fallopian mass)
Patients ≥50 years of age and postmenopausal (12 months since LMP or available blood hormone levels confirming postmenopausal status) and an isolated adnexal mass or isolated bilateral adnexal masses being surgically removed. These patients may have a final diagnosis of any of the following: benign ovarian neoplasm, borderline tumor of the ovary, or clinically early-stage OC. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Autres noms:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 7 - OC Cohort - Biopsy proven or clinically suspected ovarian cancer (OC)
Patients ≥18 years of age with ovarian cancer (OC) (clinically probable based on distribution of pelvic/abdominal masses on imaging, elevated CA-125, ascites, and/or imaging-guided biopsy proven) presenting for neoadjuvant chemotherapy or primary surgical management (debulking or staging) of their OC. The umbrella of OC also includes fallopian tube cancer and primary peritoneal cancer. All histologies are eligible for enrollment. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Autres noms:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Develop predictive models from a panel of EC-specific MDMs and validate their performance in identifying underlying EC and AEH within vaginal fluid in a larger, more diverse cohort.
Délai: 18 months
|
Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based endometrial cancer detection test performed on vaginal fluid. The phase II aspect of this biomarker development study will narrow the number of endometrial cancer MDMs within the biomarker panel in order to optimize the next phase of test development. |
18 months
|
|
Develop predictive models from a panel of OC-specific MDMs and validate their performance in identifying underlying OC within vaginal fluid and plasma in a larger, more diverse cohort.
Délai: 18 months
|
Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based ovarian cancer detection test performed on vaginal fluid. The phase II aspect of this biomarker development study will narrow the number of ovarian cancer MDMs within the biomarker panel in order to optimize the next phase of test development. |
18 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Using 95% specificity cutoffs of the final MDM EC panel, determine the false positive rate among women undergoing surgical removal of common benign gynecologic pathology
Délai: 18 months
|
As part of this biomarker test development, understanding whether common non-cancerous uterine or gynecologic conditions may also lead to the finding of currently apparent endometrial cancer-specific MDMs in vaginal fluid is critical in determining specificity, positive predictive value, and negative predictive value of the test. |
18 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jamie N. Bakkum-Gamez, M.D., Mayo Clinic
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Maladies du système endocrinien
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies utérines
- Maladies génitales, femme
- Tumeurs des glandes endocrines
- Maladies ovariennes
- Maladies annexielles
- Tumeurs génitales, femme
- Troubles gonadiques
- Conditions précancéreuses
- Maladies du col de l'utérus
- Tumeurs utérines
- Tumeurs ovariennes
- Tumeurs du col de l'utérus
- Tumeurs de l'endomètre
- Dysplasie cervicale utérine
- Hyperplasie de l'endomètre
- Techniques d'investigation
- Manipulation des échantillons
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Perforation
- Procédures chirurgicales, opératoires
- Collection d'échantillons de sang
Autres numéros d'identification d'étude
- 20-012833
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .